Susan Cheng1, Danielle Enserro2, Vanessa Xanthakis3, Lisa M Sullivan2, Joanne M Murabito4, Emelia J Benjamin5, Joseph F Polak6, Christopher J O'Donnell7, Philip A Wolf8, George T O'Connor9, John F Keaney10, Ramachandran S Vasan11. 1. National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, MA, USA Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA scheng3@partners.org. 2. Department of Biostatistics, Boston University, Boston, MA, USA. 3. National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, MA, USA Department of Biostatistics, Boston University, Boston, MA, USA Sections of Preventive Medicine, Boston University School of Medicine, Boston, MA, USA. 4. National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, MA, USA General Internal Medicine, Boston University School of Medicine, Boston, MA, USA. 5. National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, MA, USA Department of Cardiology, Boston University School of Medicine, Boston, MA, USA. 6. Department of Radiology, New England Medical Center, Boston, MA, USA. 7. National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, MA, USA Center for Population Studies, National Heart, Lung, and Blood Institute, Bethesda, MD, USA. 8. National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, MA, USA Department of Neurology, Boston University School of Medicine, Boston, MA, USA. 9. National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, MA, USA Pulmonary Center, Boston University School of Medicine, Boston, MA, USA. 10. Cardiovascular Medicine, Department of Medicine, University of Massachusetts Medical School, Boston, MA, USA. 11. National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, MA, USA Sections of Preventive Medicine, Boston University School of Medicine, Boston, MA, USA Department of Cardiology, Boston University School of Medicine, Boston, MA, USA Department of Epidemiology, Boston University School of Medicine, Boston, MA, USA.
Abstract
AIMS: Whereas endogenous carbon monoxide (CO) is cytoprotective at physiologic levels, excess CO concentrations are associated with cardiometabolic risk and may represent an important marker of progression from subclinical to clinical cardiovascular disease (CVD). METHODS AND RESULTS: In 1926 participants of the Framingham Offspring Study (aged 57 ± 10 years, 46% women), we investigated the relationship of exhaled CO, a surrogate of blood CO concentration, with both prevalent subclinical CVD and incident clinical CVD events. Presence of subclinical CVD was determined using a comprehensive panel of diagnostic tests used to assess cardiac and vascular structure and function. Individuals with the highest (>5 p.p.m.) compared with lowest (≤4 p.p.m.) CO exposure were more likely to have subclinical CVD [odds ratios (OR): 1.67, 95% CI: 1.32-2.12; P < 0.001]. During the follow-up period (mean 5 ± 3 years), 193 individuals developed overt CVD. Individuals with both high CO levels and any baseline subclinical CVD developed overt CVD at an almost four-fold higher rate compared with those with low CO levels and no subclinical disease (22.1 vs. 6.3%). Notably, elevated CO was associated with incident CVD in the presence [hazards ration (HR): 1.83, 95% CI: 1.08-3.11; P = 0.026] but not in the absence (HR: 0.80, 95% CI: 0.42-1.53; P = 0.51) of subclinical CVD (Pinteraction = 0.019). Similarly, subclinical CVD was associated with incident CVD in the presence of high but not low CO exposure. CONCLUSION: Our findings in a community-based sample suggest that elevated CO is a marker of greater subclinical CVD burden and, furthermore, a potential key component in the progression from subclinical to clinical CVD. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Whereas endogenous carbon monoxide (CO) is cytoprotective at physiologic levels, excess CO concentrations are associated with cardiometabolic risk and may represent an important marker of progression from subclinical to clinical cardiovascular disease (CVD). METHODS AND RESULTS: In 1926 participants of the Framingham Offspring Study (aged 57 ± 10 years, 46% women), we investigated the relationship of exhaled CO, a surrogate of blood CO concentration, with both prevalent subclinical CVD and incident clinical CVD events. Presence of subclinical CVD was determined using a comprehensive panel of diagnostic tests used to assess cardiac and vascular structure and function. Individuals with the highest (>5 p.p.m.) compared with lowest (≤4 p.p.m.) CO exposure were more likely to have subclinical CVD [odds ratios (OR): 1.67, 95% CI: 1.32-2.12; P < 0.001]. During the follow-up period (mean 5 ± 3 years), 193 individuals developed overt CVD. Individuals with both high CO levels and any baseline subclinical CVD developed overt CVD at an almost four-fold higher rate compared with those with low CO levels and no subclinical disease (22.1 vs. 6.3%). Notably, elevated CO was associated with incident CVD in the presence [hazards ration (HR): 1.83, 95% CI: 1.08-3.11; P = 0.026] but not in the absence (HR: 0.80, 95% CI: 0.42-1.53; P = 0.51) of subclinical CVD (Pinteraction = 0.019). Similarly, subclinical CVD was associated with incident CVD in the presence of high but not low CO exposure. CONCLUSION: Our findings in a community-based sample suggest that elevated CO is a marker of greater subclinical CVD burden and, furthermore, a potential key component in the progression from subclinical to clinical CVD. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Yeonsoo Joe; Min Zheng; Seul-Ki Kim; Sena Kim; Jamal M D Uddin; Tae Sun Min; Do Gon Ryu; Hun Taeg Chung Journal: Ann N Y Acad Sci Date: 2011-07 Impact factor: 5.691
Authors: Luz D Orozco; Matthias H Kapturczak; Berenice Barajas; Xuping Wang; Michael M Weinstein; Jack Wong; Jessy Deshane; Subhashini Bolisetty; Zory Shaposhnik; Diana M Shih; Anupam Agarwal; Aldons J Lusis; Jesus A Araujo Journal: Circ Res Date: 2007-05-10 Impact factor: 17.367
Authors: Caroline Cheng; Annemarie M Noordeloos; Viktoria Jeney; Miguel P Soares; Frans Moll; Gerard Pasterkamp; Patrick W Serruys; Henricus J Duckers Journal: Circulation Date: 2009-06-01 Impact factor: 29.690
Authors: Ben J Wu; Krishna Kathir; Paul K Witting; Konstanze Beck; Katherine Choy; Cheng Li; Kevin D Croft; Trevor A Mori; David Tanous; Mark R Adams; Antony K Lau; Roland Stocker Journal: J Exp Med Date: 2006-04-10 Impact factor: 14.307
Authors: Matthew Nayor; Danielle M Enserro; Alexa S Beiser; Susan Cheng; Charles DeCarli; Ramachandran S Vasan; Sudha Seshadri Journal: Stroke Date: 2015-12-22 Impact factor: 7.914